Drug Trial Radar · NCT06547164
A Study to Investigate the Pharmacokinetics of Midazolam After Repeated Doses of Camizestrant (AZD9833) and to Investigate the Pharmacokinetics of Camizestrant When Administered Alone and in Combination With Carbamazepine in Healthy Post-Menopausal Female Participants
Last checked: Nov 20, 2026Latest source record: Sep 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Aug 27, 2024
Primary completion
Aug 20, 2025
Study completion Aug 20, 2025
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Aug 9, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 50 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will be conducted in order to determine the effect of repeated oral doses of camizestrant on the pharmacokinetics (PK) of midazolam and to determine the effect of repeated oral titrated doses of carbamazepine on the PK of camizestrant in healthy post-menopausal female participants.
Conditions
- Healthy Participants
Interventions
MidazolamDrug
Midazolam will be administered orally.
CamizestrantDrug
Camizestrant will be administered orally.
CarbamazepineDrug
Carbamazepine will be administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Area under concentration-time curve from time 0 to infinity (AUCinf) of midazolamTime frame: Period 1 (Day 1) and Period 3 (Day 7 to Day 8)
- Part A: Area under concentrationcurve from time 0 to the last quantifiable concentration (AUClast) of midazolamTime frame: Period 1 (Day 1) and Period 3 (Day 7 to Day 8)
- Part A: Maximum observed plasma (peak) drug concentration (Cmax) of midazolamTime frame: Period 1 (Day 1) and Period 3 (Day 7 to Day 8)
- Part B: Area under concentration-time curve from time 0 to infinity (AUCinf) of camizestrantTime frame: Period 1 (Day 1 to Day 4), Period 2 (Day 22 to Day 25)
- Part B: Area under concentrationcurve from time 0 to the last quantifiable concentration (AUClast) of camizestrantTime frame: Period 1 (Day 1 to Day 4), Period 2 (Day 22 to Day 25)
- Part B: Maximum observed plasma (peak) drug concentration (Cmax) of camizestrantTime frame: Period 1 (Day 1 to Day 4), Period 2 (Day 22 to Day 25)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Research Site
Harrow, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.